ESPAC-4

ISRCTN96397434 📎

Regimen

Experimental
Gemcitabine 1000 mg/m2 d1, 8, 15 + capecitabine 1660 mg/m2 d1-21 q4w x 6 cycles.
Control
Gemcitabine 1000 mg/m2 d1, 8, 15 q4w x 6 cycles.

Population

Resected PDAC (R0/R1), post-surgery within 12 weeks, ECOG PS 0-2, UK/European multicenter.

Key finding

ESPAC-4 established adjuvant gemcitabine + capecitabine (GemCap) as a new standard of care for resected PDAC patients, outperforming gemcitabine monotherapy. GemCap remains the preferred adjuvant regimen for patients unable to tolerate mFFX (the subsequent PRODIGE-24 winner).

Source: PMID 28129987

Timeline

    Guideline citations

    • NCCN PANCREATIC (p.54)